Application of Network Pharmacology in Elucidating Molecular Mechanisms of Traditional Drugs for Pulmonary Fibrosis

Traditional medicines used for respiratory problems have been found beneficial in pulmonary fibrosis. However, traditional medicines are looked down upon compared to conventional therapy, due to the multiple components that face difficulty in predicting their efficacy. Network pharmacology uses biological databases, bioinformatics, and computational models for diseases and drugs to provide molecular mechanisms. This review aims to compile the articles on network pharmacology applied to discover the molecular mechanisms of traditional medicines and discuss limitations and future aspects in treating the complex pathophysiology of pulmonary fibrosis. Literatures were shortlisted from Scopus, Web of Science, and PubMed by utilizing the PRISMA search strategy. The term network pharmacology was coined in 2007. Hence, the publications from 2007 to June 2024 were considered. Many traditional medicines were widely used therapeutically and have been established for molecular mechanisms with this approach, supported by in vitro or in vivo models. Formulations from Traditional Chinese Medicine are highly explored for treating pulmonary fibrosis. However, other traditional medicines, such as Ayurveda, must be pitched to rediscover the rich heritage of knowledge. Many of the studies lack the appropriate techniques, such as characterization, bioinformatics, pharmacokinetics, and pharmacodynamics utilization. Studies that followed this approach in preclinical evaluation support scientific evidence for clinical applications. The broad-spectrum application of network pharmacology is needed to provide a theoretical underpinning for safe drug development with its holistic approach and promising preclinical results, offering potential as complementary therapies with multiple drug targets in pulmonary fibrosis. Adopting broad-spectrum techniques, a few traditional medicines have started clinical trials and enhanced respiratory functions. By resolving the interlinks that exist in the progression of the disease, focusing on the limitations and application of this broad approach will bring about future therapeutics.

Authors

Institutions

Publication Details

Journal
Revista Brasileira de Farmacognosia
Published
2025-11-05
DOI
https://doi.org/10.1007/s43450-025-00706-z
Citations
2
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
3.04
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Application of Network Pharmacology in Elucidating Molecular Mechanisms of Traditional Drugs for Pulmonary Fibrosis

Yogendra Nayak, Bonthu Satyanarayana, Bharath Harohalli Byregowda, Fayaz SM et al.
2 citations
Revista Brasileira de Farmacognosia
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
3.04
article

Application of Network Pharmacology in Elucidating Molecular Mechanisms of Traditional Drugs for Pulmonary Fibrosis

Yogendra Nayak, Bonthu Satyanarayana, Bharath Harohalli Byregowda, Fayaz SM, Krishnaprasad Baby, Megh Pravin Vithalkar
article en
2 citations

Abstract

Traditional medicines used for respiratory problems have been found beneficial in pulmonary fibrosis. However, traditional medicines are looked down upon compared to conventional therapy, due to the multiple components that face difficulty in predicting their efficacy. Network pharmacology uses biological databases, bioinformatics, and computational models for diseases and drugs to provide molecular mechanisms. This review aims to compile the articles on network pharmacology applied to discover the molecular mechanisms of traditional medicines and discuss limitations and future aspects in treating the complex pathophysiology of pulmonary fibrosis. Literatures were shortlisted from Scopus, Web of Science, and PubMed by utilizing the PRISMA search strategy. The term network pharmacology was coined in 2007. Hence, the publications from 2007 to June 2024 were considered. Many traditional medicines were widely used therapeutically and have been established for molecular mechanisms with this approach, supported by in vitro or in vivo models. Formulations from Traditional Chinese Medicine are highly explored for treating pulmonary fibrosis. However, other traditional medicines, such as Ayurveda, must be pitched to rediscover the rich heritage of knowledge. Many of the studies lack the appropriate techniques, such as characterization, bioinformatics, pharmacokinetics, and pharmacodynamics utilization. Studies that followed this approach in preclinical evaluation support scientific evidence for clinical applications. The broad-spectrum application of network pharmacology is needed to provide a theoretical underpinning for safe drug development with its holistic approach and promising preclinical results, offering potential as complementary therapies with multiple drug targets in pulmonary fibrosis. Adopting broad-spectrum techniques, a few traditional medicines have started clinical trials and enhanced respiratory functions. By resolving the interlinks that exist in the progression of the disease, focusing on the limitations and application of this broad approach will bring about future therapeutics.

Revista Brasileira de FarmacognosiaVol. 35(6)
Manipal Academy of Higher Education (IN), Institute of Medical Sciences (IN)
Openalex Percentile: Top 7%
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
3.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.